^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Cholangiocarcinoma

    Related cancers:
    21h
    FAPI PET RDRC: Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jul 2026 --> Jun 2025
    Trial primary completion date
    1d
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)
    P1, N=119, Active, not recruiting, Boehringer Ingelheim | Trial completion date: May 2026 --> Feb 2026
    Trial completion date
    |
    TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • TP53 wild-type
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    1d
    A Rare and Aggressive Klatskin Tumor Revealed by Magnetic Resonance Cholangiopancreatography (MRCP): A Diagnostic Case Report. (PubMed, Cureus)
    The patient was promptly referred to a specialized hepatobiliary unit for evaluation of curative-intent resection. This case highlights how contemporary high-resolution MRCP combined with extreme CA 19-9 elevation can establish a confident noninvasive diagnosis of Klatskin tumor when initial ERCP fails, dramatically shortening diagnostic delay and accelerating the pathway to potentially curative surgery.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    1d
    FORTITUDE-301: A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (clinicaltrials.gov)
    P1/2, N=260, Completed, Amgen | Active, not recruiting --> Completed
    Trial completion • Pan tumor
    |
    FGFR2 overexpression
    |
    bemarituzumab (AMG 552)
    1d
    Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (clinicaltrials.gov)
    P2, N=27, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    2d
    Total Laparoscopic vs Open Pancreaticoduodenectomy for the Treatment of Periampullary Adenocarcinomas (clinicaltrials.gov)
    P=N/A, N=30, Completed, Theodor Bilharz Research Institute
    New trial
    2d
    Spontaneous Regression of Intrahepatic Adenocarcinoma after Needle Biopsy: A Case Report and Literature Review. (PubMed, Surg Case Rep)
    This case highlights the possibility of tumor regression in intrahepatic adenocarcinoma following EUS-FNA, potentially triggered by an immune response.
    Journal
    |
    CD8 (cluster of differentiation 8)
    3d
    Development of A Risk Assessment Model for Venous Thromboembolism among Patients with Cholangiocarcinoma. (PubMed, Clin Appl Thromb Hemost)
    This model may assist clinicians in identifying individuals for risk of VTE. External validation is warranted to confirm its generalizability.
    Retrospective data • Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    3d
    Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors. (PubMed, Clin Cancer Res)
    The complementary activity of lirafugratinib and futibatinib against FGFR2 kinase domain mutations supports their sequential use, when precise resistance mutations are detected in patients.
    Journal
    |
    FGFR2 (Fibroblast growth factor receptor 2) • BICC1 (BicC Family RNA Binding Protein 1)
    |
    FGFR2 mutation
    |
    Lytgobi (futibatinib) • lirafugratinib (RLY-4008)
    4d
    HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) (clinicaltrials.gov)
    P2, N=39, Recruiting, Oslo University Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    4d
    Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. (PubMed, Hepatology)
    Our large-scale GWAS highlights new genetic variants and HLA-linked mechanisms underlying CCA susceptibility. Integrating multi-step post-GWAS approaches enhances understanding of CCA pathogenesis and may facilitate the development of risk biomarkers for early detection and precision prevention strategies.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha)
    5d
    Gross Intrahepatic Mass Formation Predicts the Primary Site of Perihilar Cholangiocarcinoma Based on Molecular Pathologic Studies. (PubMed, J Hepatobiliary Pancreat Sci)
    Gross intrahepatic mass formation indicates an intrahepatic contextual profile and provides a useful criterion for subclassifying hCCA. This contextual framework shows that hCCA-M and hCCA-NM represent biologically distinct tumor groups.
    Journal
    |
    CLDN18 (Claudin 18) • MSLN (Mesothelin) • SERPINA1 (Serpin Family A Member 1)